J
Jan Basile
Researcher at United States Department of Veterans Affairs
Publications - 11
Citations - 326
Jan Basile is an academic researcher from United States Department of Veterans Affairs. The author has contributed to research in topics: Dyslipidemia & ACE inhibitor. The author has an hindex of 6, co-authored 11 publications receiving 317 citations. Previous affiliations of Jan Basile include Medical University of South Carolina.
Papers
More filters
Journal ArticleDOI
Baseline Characteristics of Participants in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
Richard H. Grimm,Karen L. Margolis,Vasilios Papademetriou,William C. Cushman,Charles E. Ford,Judy Bettencourt,Michael H. Alderman,Jan Basile,Henry R. Black,Vincent DeQuattro,John H. Eckfeldt,C. Morton Hawkins,H. Mitchell Perry,Michael A. Proschan +13 more
TL;DR: The ALLHAT study is a randomized, double-blind, active-controlled clinical trial designed to determine whether the incidence of the primary outcome, fatal coronary heart disease or nonfatal myocardial infarction, differs between treatment initiation with a diuretic versus each of 3 other antihypertensive drugs.
Journal ArticleDOI
Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Henry R. Black,Barry R. Davis,Joshua I. Barzilay,Chuke Nwachuku,Chuke Nwachuku,Charles Baimbridge,Horia Marginean,Jackson T. Wright,Jan Basile,Nathan D. Wong,Paul K. Whelton,Richard A. Dart,Udho Thadani +12 more
TL;DR: Despite a less favorable metabolic profile, thiazide-like diuretic initial therapy for hypertension offers similar, and in some instances possibly superior, CVD outcomes in older hypertensive adults with metabolic syndrome, as compared with treatment with CCBs and ACE inhibitors.
Journal ArticleDOI
Achieving blood pressure goals: why aren't we?
TL;DR: For the success of clinical trials to be reproduced in clinical practice, clinicians must recognize the importance of treating BP to goal, emphasize to patients the need to adhere to treatments, and provide persistent, goal‐targeted therapy.
Journal ArticleDOI
Addressing the global cardiovascular risk of hypertension, dyslipidemia, and insulin resistance in the southeastern United States.
Mark C. Houston,Ralph G. Hawkins,Jan Basile,William Bestermann,Brent M. Egan,Daniel T. Lackland,Michael A. Moore,Carlos M. Ferrario,James W. Reed,Philip Rogers,Daniel Wise +10 more
TL;DR: The components of the metabolic syndrome are analyzed, its pathophysiology is discussed, and an approach to the quantitative analysis of the risk factors contributing to excess cardiovascular death in the region is recommended.
Journal ArticleDOI
Renal Sympathetic Denervation for Blood Pressure Control: A Review of the Current Evidence and Ongoing Studies
TL;DR: The principal focus of this article is to review the developments in renal sympathetic denervation for the treatment of resistant hypertension.